recommendations were based is observational with potential for bias. Methods A pilot randomized controlled trial was conducted in 12 hemodialysis centers in Canada and Australia. Individuals aged 55…

This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more

in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

Fluid restriction is frequently recommended to patients with chronic heart failure, but randomized clinical trials assessing the effects of fluid restriction remain scarce. In this multicenter open-la...

This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD.  These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...

This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?

ALT: a person is measuring their weight on a scale that goes up to 40

AbstractBackground. Minimal change disease (MCD) is a common pathological type of nephrotic syndrome in children and adults, and the mechanisms remain obsc

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

The European label for Ozempic will be updated to include an indication for risk reduction for events related to kidney disease.

Freely Filtered 061: Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients.

Simon Smith, MDInternQueen Elizabeth Hospital, Gateshead, UK Jamie Willows, MDRenal fellowFreeman Hospital, Newcastle Upon Tyne, UK Diabetic ketoacidosis

YouTube video by Joel Topf

Metformin, together with lifestyle intervention, is considered first-line treatment for glycemic management in people with type 2 diabetes. Despite this widespread use, one of the areas of longstandin...

Click on the article title to read more.

Background: In patients with advanced chronic kidney disease (CKD), the effects of initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) on ...